Medicus Pharma Reports $20.9 Million Net Loss in Latest Quarter, Highlights Acquisition of Antev Limited

Medicus Pharma Ltd. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $20.9 million for the quarter, compared to a loss of $2.3 million in the same period last year. For the nine months ending September 30, 2025, the net loss totaled $32.2 million, up from $7.6 million in the prior year. The increase in losses is attributed to heightened operational expenses, particularly in general and administrative costs, which surged to $12.7 million from $5.4 million year-over-year, and research and development expenses, which rose to $5.1 million from $2.2 million.

The company’s total operating expenses for the third quarter reached $15.4 million, a substantial increase from $2.3 million in the previous year. This rise is largely due to the acquisition of Antev Limited, which added $8.7 million in in-process research and development costs related to the Teverelix project. Medicus Pharma's total assets increased to $10.0 million as of September 30, 2025, up from $5.6 million at the end of 2024, primarily driven by cash and cash equivalents, which rose to $8.7 million from $4.2 million.

In terms of strategic developments, Medicus Pharma completed the acquisition of Antev Limited on August 29, 2025, acquiring 98.6% of its shares for approximately $2.97 million in cash and 1.6 million common shares. This acquisition is expected to enhance the company’s product pipeline, particularly in the development of Teverelix, a next-generation GnRH antagonist aimed at treating prostate cancer and acute urinary retention. The company also engaged in various financing activities, including a Regulation A offering that raised $4.2 million and a public offering that generated $7.0 million in gross proceeds.

Operationally, the company has seen an increase in its employee headcount, reflecting its expansion efforts. As of September 30, 2025, Medicus Pharma had 22,029,144 common shares outstanding, a significant increase from the previous year. The company is also actively pursuing geographic expansion, with ongoing clinical trials in the United States and plans to initiate studies in the United Arab Emirates. Despite these advancements, the company faces challenges, including the need for additional capital to sustain operations and the inherent risks associated with clinical trials and product development.

Looking ahead, Medicus Pharma anticipates continued operating losses as it invests in research and development. The company has expressed concerns regarding its ability to secure additional financing, which is critical for its ongoing projects and overall business strategy. Management has indicated that without sufficient capital, it may need to implement cost-cutting measures that could delay or hinder its product commercialization efforts. The company remains focused on integrating Antev into its operations and advancing its clinical programs, while also navigating the complexities of being a publicly traded entity.